

AMENDMENTS TO THE CLAIMS

1. (previously presented) A composition for inhibiting COX-2 biosynthesis or COX-2- and NFχB-biosynthesis comprising a therapeutically effective amount of the compound of formula I



I

wherein R^1 and R^4 represent either hydrogen or together a bond, R^5, R^6, R^7, R^8 represent independently of each other hydrogen, hydroxy or methoxy; in addition R^7 represents a sugar substituent,

R^2 and R^3 represent hydrogen, hydroxy, methoxy, or



, wherein $R^{2'}$, $R^{3'}$, $R^{5'}$, and $R^{6'}$ are independently of each other hydrogen, hydroxy or methoxy, wherein $R^{4'}$ is H, flavone, 5-OH-flavone, 7-OH-flavone and 7,8-(OH)2-flavone, with the proviso, that R^2 or R^3 is represented by the phenyl-ring optionally substituted and a pharmaceutically acceptable carrier.

2. (previously presented) A composition for inhibiting COX-2 biosysthesis or NFχB-biosynthesis or NFχB and COX-2 biosynthesis comprising a therapeutically effective amount of the compound of formula II



(II)

wherein R^3 represents hydrogen, hydroxy or methoxy and R^5, R^6, R^7, R^8, $R^{2'}$, $R^{3'}$, $R^{5'}$, $R^{6'}$ are as given in claim 1 and a pharmaceutical acceptable carrier.

3-12. (canceled)

13. (currently amended) The composition of claim 1, wherein the sugar substituent is selected from the group consisting of ~~hydrogen, hydroxy, methoxy,~~ glucoside, rutinosid, manno gluco pyransyl, and aprosylglucoside.